title: OnabotulinumtoxinA in urinary incontinence: Prospective Study of a Case Series.
abstract: OBJECTIVE
  To assess the safety and efficacy of a single intravesical injection of onabotulinumtoxinA (OnaBTA) for treating urge urinary incontinence (UUI) in women.
  
  
  METHODS
  We performed a prospective case-series study of consecutive patients with refractory UUI treated with an intravesical injection of OnaBTA. The patients were administered 100 units of OnaBTA injected into the bladder wall following 4 weeks of flushing with anticholinergic agents or beta 3 agonists. The urodynamic and clinical endpoints were evaluated before and 6 months after the injection of OnaBTA. The primary study endpoint was the number of episodes of urinary leakage.
  
  
  RESULTS
  A total of 204 of the 210 selected patients conducted a valid visit 6 months after the therapeutic application. At 6 months of treatment with OnaBTA, 110 (53.9%) patients remained continent and were considered a success. However, 57 (27.9%) patients experienced one episode of urinary leakage per day, and 37 (18.2%) had 2 or more. In terms of the urodynamic parameters, we observed the following changes: increase in maximum bladder capacity (P<.0001) and reduced maximum pressure of the detrusor (P<.0001). In terms of the safety profile, 8 (3.9%) patients had self-limiting haematuria during the procedure, which resolved spontaneously, and 9 (4.4%) patients had acute urinary retention that required intermittent catheterisation.
  
  
  CONCLUSIONS
  This study supports the use of OnabotulinumtoxinA in patients with urge urinary incontinence that does not respond to medical treatment.
authors.affiliation: Departamento de Obstetricia y Ginecología, Complejo Hospitalario Universitario Insular Materno-Infantil Las Palmas de Gran Canaria, Las Palmas, España. Electronic address: aliciammartinez@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Martín-Martínez
authors.affiliation: Departamento de Obstetricia y Ginecología, Complejo Hospitalario Universitario Insular Materno-Infantil Las Palmas de Gran Canaria, Las Palmas, España.
authors.forename: A
authors.initials: A
authors.lastname: Fernández-Mederos
authors.affiliation: Departamento de Obstetricia y Ginecología, Complejo Hospitalario Universitario Insular Materno-Infantil Las Palmas de Gran Canaria, Las Palmas, España.
authors.forename: J Á
authors.initials: JÁ
authors.lastname: García-Hernández
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D053202:Urinary Incontinence, Urge / Q000188:drug therapy
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A
keywords: Botulinum toxin; Escapes de orina; Incontinencia urinaria; Sandvik severity index; Toxina botulínica; Urinary incontinence; Urine leakage; Índice de gravedad de Sandvik